Skip to content


Custom engineering services, scalable transient and stable cell line solutions.

Design and optimise

We custom-build Lentiviral plasmids with your transgene of interest, utilising our proprietary expression system to improve product safety, yield and quality.

License for manufacture

Our cGMP-compliant suspension HEK293 transient production system and stable packaging cell lines provide scalable and efficient systems for high volume, high titre lentiviral vector production.

Scale up

Our process development experts support you to expedite on-boarding of technologies and facilitate technology transfer.

Lentivirus at the edge of impossible

OXGENE has re-developed the lentiviral plasmid system to facilitate yields greater than 1x10⁸ TU/ml, and generated manufacture-ready suspension-mode lentiviral packaging cell lines to facilitate large scale lentiviral production. This system maximizes process reproducibility and reduces manufacturing costs for some of the industry’s most exciting therapies.

Lentiviral Transient System

OXGENE has optimised its 3rd generation, self-inactivating (SIN) lentivirus packaging plasmids to improve safety, reduce homology and increase yield. Each plasmid is built on an optimized and minimized backbone after multiple screening experiments to identify ideal configurations and stoichiometries. This generates a well-characterized, high-titre lentiviral system that outperforms all other commercially available equivalents in our proprietary serum-free, suspension HEK293 cell line.

Our plasmids are immediately available for evaluation purposes and can also be accessed through our technology partner Aldevron. We can also customise this system to clone any gene of interest, or for novel/non-standard pseudotyping.  

Our transient lentiviral expression platform transitions seamlessly to a stable lentiviral packaging cell line, which allows for single plasmid transfection, and so reduces process complexity and cost of goods, and simplifies the supply chain.

Lentiviral Packaging and Producer Cell Lines

OXGENE has successfully developed a suspension-mode, stable lentiviral packaging cell line platform using a proprietary Tet-inducible system. This demonstrates high titre lentiviral production with single plasmid transfection in both shake flask and bioreactor.

Our packaging cell lines also form the basis of our GMP-compliant, animal component free producer cell lines, which permit transfection-free, large-scale production of lentiviral vectors for cell and gene therapies.

We used a fully-defined, serum/animal component-free process to generate both our packaging and producer GMP-compliant HEK293 cell lines. Cell lines do not contain the SV40 Large-T antigen and remain stable in the absence of antibiotic selection, minimising the regulatory risks in transitioning to clinical use.

Genetic medicine has experienced tremendous growth with the approval of multiple products that dramatically improve life. Lentiviral vectors are the key component for manufacturing many of these treatments. The free availability of lentiviral packaging plasmids will significantly reduce the time and cost to develop and commercialize these products.

Michael Chambers, CEO of Aldevron

AAV Engineering

Optimised AAV Design, Precision Engineering and Scalable Production

Adenovirus Engineering

Optimised Adenovirus Engineering and Proprietary TERA system

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.


Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of qualify control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.